{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:21:15Z","timestamp":1777713675534,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ymgme.2022.106981","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T12:05:53Z","timestamp":1671710753000},"page":"106981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study"],"prefix":"10.1016","volume":"138","author":[{"given":"Jonas","family":"M\u00fcntze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kolja","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cybulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lora","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurcan","family":"\u00dc\u00e7eyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nordbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ymgme.2022.106981_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ymgme.2022.106981_bb0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106981_bb0015","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106981_bb0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001691","article-title":"\u03b1-Galactosidase a genotype N215S induces a specific cardiac variant of Fabry disease","volume":"10","author":"Oder","year":"2017","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2022.106981_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ymgme.2022.106981_bb0030","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry DISEASEA randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ymgme.2022.106981_bb0035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1\u2013galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106981_bb0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases \u03b1-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2022.106981_bb0045","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ymgme.2022.106981_bb0050","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ymgme.2022.106981_bb0055","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.ymgme.2022.106981_bb0060","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"issue":"1118","key":"10.1016\/j.ymgme.2022.106981_bb0065","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/postgradmedj-2018-136056","article-title":"Hot topics in Fabry disease","volume":"94","author":"Cairns","year":"2018","journal-title":"Postgrad. Med. J."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106981_bb0070","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: a review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ymgme.2022.106981_bb0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08037051.2015.1121706","article-title":"Adherence to medication and drug monitoring in apparent treatment-resistant hypertension","volume":"25","author":"Esk\u00e5s","year":"2016","journal-title":"Blood Press."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106981_bb0080","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol."},{"issue":"4","key":"10.1016\/j.ymgme.2022.106981_bb0085","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2022.106981_bb0090","article-title":"Treatment of fabry disease with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)","author":"Lenders","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"10.1016\/j.ymgme.2022.106981_bb0095","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"M\u00fcntze","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2022.106981_bb0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med. Care"},{"issue":"6","key":"10.1016\/j.ymgme.2022.106981_bb0105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"issue":"2","key":"10.1016\/j.ymgme.2022.106981_bb0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00439716","article-title":"An overview of generic health-related quality of life measures for HIV research","volume":"1","author":"Hays","year":"1992","journal-title":"Qual. Life Res."},{"issue":"20","key":"10.1016\/j.ymgme.2022.106981_bb0115","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ymgme.2022.106981_bb0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/109019819001700303","article-title":"A patient education program to improve adherence rates with antituberculosis drug regimens","volume":"17","author":"Morisky","year":"1990","journal-title":"Health Educ. Q."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106981_bb0125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jclinepi.2010.09.002","article-title":"Improving the measurement of self-reported medication nonadherence: response to authors","volume":"64","author":"Morisky","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.ymgme.2022.106981_bb0130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s13023-020-01580-9","article-title":"English version of the self-administered Fabry Pain Questionnaire for adult patients","volume":"15","author":"Jovanovic","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ymgme.2022.106981_bb0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13023-015-0325-7","article-title":"Self-administered version of the Fabry-associated pain questionnaire for adult patients","volume":"10","author":"Magg","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"10261","key":"10.1016\/j.ymgme.2022.106981_bb0140","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(20)32007-9","article-title":"Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe","volume":"396","author":"Han","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ymgme.2022.106981_bb0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/kisup.2012.64","article-title":"Chapter 1: Definition and classification of CKD","volume":"3","year":"2013","journal-title":"Kidney International Supplements"},{"issue":"4","key":"10.1016\/j.ymgme.2022.106981_bb0150","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study","volume":"6","author":"Germain","year":"2018","journal-title":"Mol Genet Genomic Med"},{"issue":"1","key":"10.1016\/j.ymgme.2022.106981_bb0155","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","article-title":"Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant","volume":"11","author":"Lenders","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.ymgme.2022.106981_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1912","article-title":"Gene variants of unknown significance in Fabry disease: clinical characteristics of c.376A>G (p.Ser126Gly)","volume":"10","author":"Lau","year":"2022","journal-title":"Mol Genet Genomic Med"},{"issue":"8","key":"10.1016\/j.ymgme.2022.106981_bb0165","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/heartjnl-2019-315933","article-title":"Cardiomyopathy associated with the Ala143Thr variant of the \u03b1-galactosidase A gene","volume":"106","author":"Valtola","year":"2020","journal-title":"Heart"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2022.106981_bb0170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","article-title":"Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study","volume":"131","author":"Feldt-Rasmussen","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2022.106981_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.medcli.2018.10.023","article-title":"Adherence to treatment of hypertension, hypercholesterolaemia and diabetes in an elderly population of a Spanish cohort","volume":"153","author":"Moreno Juste","year":"2019","journal-title":"Med. Clin. (Barc.)"},{"issue":"1","key":"10.1016\/j.ymgme.2022.106981_bb0180","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13023-018-0813-7","article-title":"Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial","volume":"13","author":"Schiffmann","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.ymgme.2022.106981_bb0185","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry\u2019s disease with Migalastat: outcome from a prospective observational multicenter study (FAMOUS)","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.ymgme.2022.106981_bb0190","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","article-title":"Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data","volume":"28","author":"Riccio","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106981_bb0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222004590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222004590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:53:30Z","timestamp":1761090810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719222004590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1096719222004590"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.106981","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.106981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106981"}}